Will the FDA approve Keytruda for muscle-invasive bladder cancer by its Aug 17 decision date?
50% of users predicted YES — the community got this one right. 2 predictions cast.
The FDA approved Keytruda (pembrolizumab) and Keytruda Qlex, each combined with Padcev (enfortumab vedotin-ejfv), as neoadjuvant and adjuvant treatment for adults with muscle-invasive bladder cancer, with Merck, Astellas and Pfizer announcing the decision around July 10-13, 2026. The approval extended the combination's use to all patients eligible for bladder-removal surgery (cystectomy), not only those unable to tolerate cisplatin chemotherapy, making it the first platinum-free regimen cleared for this broader muscle-invasive bladder cancer population. Because the approval was announced in mid-July, well ahead of the August 17 decision-date window referenced in the question, the treatment was already approved by the time that date arrived. The decision was based on trial data showing patients on the Keytruda-Padcev combination had improved progression-free and overall survival compared with standard cisplatin-based chemotherapy given before surgery. Community sentiment on the question was evenly split at 50% predicting approval, and the approval had, in fact, already been granted by the time of resolution, consistent with the yes side of that split.